12 June 2017 - The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

The justices, in a 9-0 ruling, overturned a lower court's decision that had prevented Swiss pharmaceutical company Novartis from selling its copycat version of California-based Amgen's  Neupogen until six months after the U.S. FDA approved it.

Read Reuters article